ORIC — Oric Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1796280 ·
Last close
$8.00
Market Cap
$829.22M
52W High
$14.68
52W Low
$7.23
ADV30
1,792,762
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -51,551,000 | -48,076,000 | 366,886,000 | 33,846,000 | 27,383,000 |
| Jun 2026 | 0 | — | -45,296,000 | -41,492,000 | 404,685,000 | 37,483,000 | 23,429,000 |
| Mar 2026 | 0 | — | -39,619,000 | -35,767,000 | 436,762,000 | 56,396,000 | 21,205,000 |
| Dec 2025 | 0 | — | -34,551,000 | -30,505,000 | 408,890,000 | 45,669,000 | 24,528,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,638,000
Investing CF
$-99,662,000
Financing CF
$172,919,000
CapEx
$-620,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.35
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-769,501,000
Inventory
—
Receivables
—
ST Investments
$227,278,000
EBIT TTM
$-156,137,000
Pretax Income TTM
$-140,351,000
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -143,004,000 | -129,468,000 | 408,890,000 | 24,528,000 | 384,362,000 | -110,970,000 |
| Dec 2024 | 0 | -142,895,000 | -127,847,000 | 274,142,000 | 31,020,000 | 243,122,000 | -112,662,000 |
| Dec 2023 | 0 | -110,780,000 | -100,697,000 | 252,007,000 | 27,919,000 | 224,088,000 | -85,688,000 |
| Dec 2022 | 0 | -86,767,000 | -89,122,000 | 247,178,000 | 24,827,000 | 222,351,000 | -75,143,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-140,351,000
OpCashFlow TTM
—
Assets (Latest)
$404,685,000
Forward EPS
$-1.61
Max Pain — expiry 2027-01-15
max pain strike: $10.00 · spot: $7.65 · call oi: 3,044 · put oi: 2,361Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SNDX | Syndax Pharmaceuticals Inc | $828.26M | $9.20 | — |
| CTY | CITY THERAPEUTICS, INC. | $846.44M | $17.50 | — |
| RIGL | RIGEL PHARMACEUTICALS INC | $808.18M | $42.92 | — |
| IRWD | IRONWOOD PHARMACEUTICALS INC | $806.23M | $4.87 | — |
| PHAR | Pharming Group N.V. | $853.58M | $12.06 | — |
News headlines (Yahoo Finance, 1h cache)
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 21:30 · Yahoo
ORIC® Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-03 21:01 · Yahoo
ORIC Pharmaceuticals (ORIC) Stock Sees Modest Fair Value Lift On Trial Catalyst Optimism
2026-10-27 10:12 · Yahoo
ORIC Pharmaceuticals Sinks 22% as J&J Presents Rival Prostate Cancer Data
2026-10-26 16:39 · Yahoo
Oric Pharmaceuticals’ Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Study
2026-10-23 17:04 · Yahoo
ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2
2026-10-23 07:15 · Yahoo
ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase
2026-10-23 07:15 · Yahoo
ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026
2026-10-21 04:26 · Yahoo
ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026
2026-10-19 12:00 · Yahoo
Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?
2026-10-08 17:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.